IL
Illinois House Bill HB2346

Illinois 2025-2026 Regular Session

Illinois House Bill HB2346 Compare Versions

OldNewDifferences
1-HB2346 EngrossedLRB104 06540 BDA 16576 b HB2346 Engrossed LRB104 06540 BDA 16576 b
2- HB2346 Engrossed LRB104 06540 BDA 16576 b
1+104TH GENERAL ASSEMBLY State of Illinois 2025 and 2026 HB2346 Introduced , by Rep. Laura Faver Dias SYNOPSIS AS INTRODUCED: 410 ILCS 715/5410 ILCS 715/45410 ILCS 715/55410 ILCS 715/70 new Amends the Illinois Drug Reuse Opportunity Program Act. Requires the Illinois Department of Public Health: (1) to develop, maintain, and publish on its website information regarding the names and locations of pharmacies participating in the program; (2) to educate pharmacies in the State about the program and how to participate in it voluntarily; (3) to develop and publish educational materials to allow program participants and the Department to inform the general public about the purposes and benefits of the program; and (4) to collect information from participants and publish the information in an annual report to the General Assembly by December 31 of each calendar year, beginning December 31, 2026. Specifies that records maintained under the Act are subject to access by the Department upon request. Defines "Department". LRB104 06540 BDA 16576 b A BILL FOR 104TH GENERAL ASSEMBLY State of Illinois 2025 and 2026 HB2346 Introduced , by Rep. Laura Faver Dias SYNOPSIS AS INTRODUCED: 410 ILCS 715/5410 ILCS 715/45410 ILCS 715/55410 ILCS 715/70 new 410 ILCS 715/5 410 ILCS 715/45 410 ILCS 715/55 410 ILCS 715/70 new Amends the Illinois Drug Reuse Opportunity Program Act. Requires the Illinois Department of Public Health: (1) to develop, maintain, and publish on its website information regarding the names and locations of pharmacies participating in the program; (2) to educate pharmacies in the State about the program and how to participate in it voluntarily; (3) to develop and publish educational materials to allow program participants and the Department to inform the general public about the purposes and benefits of the program; and (4) to collect information from participants and publish the information in an annual report to the General Assembly by December 31 of each calendar year, beginning December 31, 2026. Specifies that records maintained under the Act are subject to access by the Department upon request. Defines "Department". LRB104 06540 BDA 16576 b LRB104 06540 BDA 16576 b A BILL FOR
2+104TH GENERAL ASSEMBLY State of Illinois 2025 and 2026 HB2346 Introduced , by Rep. Laura Faver Dias SYNOPSIS AS INTRODUCED:
3+410 ILCS 715/5410 ILCS 715/45410 ILCS 715/55410 ILCS 715/70 new 410 ILCS 715/5 410 ILCS 715/45 410 ILCS 715/55 410 ILCS 715/70 new
4+410 ILCS 715/5
5+410 ILCS 715/45
6+410 ILCS 715/55
7+410 ILCS 715/70 new
8+Amends the Illinois Drug Reuse Opportunity Program Act. Requires the Illinois Department of Public Health: (1) to develop, maintain, and publish on its website information regarding the names and locations of pharmacies participating in the program; (2) to educate pharmacies in the State about the program and how to participate in it voluntarily; (3) to develop and publish educational materials to allow program participants and the Department to inform the general public about the purposes and benefits of the program; and (4) to collect information from participants and publish the information in an annual report to the General Assembly by December 31 of each calendar year, beginning December 31, 2026. Specifies that records maintained under the Act are subject to access by the Department upon request. Defines "Department".
9+LRB104 06540 BDA 16576 b LRB104 06540 BDA 16576 b
10+ LRB104 06540 BDA 16576 b
11+A BILL FOR
12+HB2346LRB104 06540 BDA 16576 b HB2346 LRB104 06540 BDA 16576 b
13+ HB2346 LRB104 06540 BDA 16576 b
314 1 AN ACT concerning health.
415 2 Be it enacted by the People of the State of Illinois,
516 3 represented in the General Assembly:
617 4 Section 5. The Illinois Drug Reuse Opportunity Program Act
7-5 is amended by changing Sections 5, 45, and 55 and by adding
8-6 Section 70 as follows:
9-7 (410 ILCS 715/5)
10-8 Sec. 5. Definitions. In this Act:
11-9 "Controlled substance" means a drug, substance, or
12-10 immediate precursor in Schedules I through V of 21 CFR 1308.
13-11 "Department" means the Illinois Department of Public
14-12 Health.
15-13 "Dispense" has the same meaning as defined in Section 3 of
16-14 the Pharmacy Practice Act.
17-15 "Donor" means any person, including an individual member
18-16 of the public, or any entity legally authorized to possess
19-17 medicine, including, but not limited to, a wholesaler or
20-18 distributor, third party logistic provider, pharmacy,
21-19 dispenser, clinic, surgical or health center, detention and
22-20 rehabilitation center, jail, prison laboratory, medical or
23-21 pharmacy school, prescriber or other health care professional,
24-22 long-term care facility, or healthcare facility. "Donor"
25-23 includes government agencies and entities that are federally
18+5 is amended by changing Sections 5, 45, 55, and 70 as follows:
19+6 (410 ILCS 715/5)
20+7 Sec. 5. Definitions. In this Act:
21+8 "Controlled substance" means a drug, substance, or
22+9 immediate precursor in Schedules I through V of 21 CFR 1308.
23+10 "Department" means the Illinois Department of Public
24+11 Health.
25+12 "Dispense" has the same meaning as defined in Section 3 of
26+13 the Pharmacy Practice Act.
27+14 "Donor" means any person, including an individual member
28+15 of the public, or any entity legally authorized to possess
29+16 medicine, including, but not limited to, a wholesaler or
30+17 distributor, third party logistic provider, pharmacy,
31+18 dispenser, clinic, surgical or health center, detention and
32+19 rehabilitation center, jail, prison laboratory, medical or
33+20 pharmacy school, prescriber or other health care professional,
34+21 long-term care facility, or healthcare facility. "Donor"
35+22 includes government agencies and entities that are federally
36+23 authorized to possess medicine, including, but not limited to,
2637
2738
2839
29- HB2346 Engrossed LRB104 06540 BDA 16576 b
30-
31-
32-HB2346 Engrossed- 2 -LRB104 06540 BDA 16576 b HB2346 Engrossed - 2 - LRB104 06540 BDA 16576 b
33- HB2346 Engrossed - 2 - LRB104 06540 BDA 16576 b
34-1 authorized to possess medicine, including, but not limited to,
35-2 drug manufacturers, repackagers, relabelers, outsourcing
36-3 facilities, health care facilities operated by the U.S.
37-4 Department of Veterans Affairs, and prisons.
38-5 "Drug" means a prescription drug, over-the-counter drug,
39-6 or supplies needed to administer a prescription or
40-7 over-the-counter drug.
41-8 "Eligible patient" means an individual:
42-9 (1) with a prescription for the drug, if a
43-10 prescription is required to dispense the drug, or who
44-11 reports symptoms treated by the drug if the drug is
45-12 over-the-counter; and
46-13 (2) who is registered with the drug's manufacturer in
47-14 accordance with federal Food and Drug Administration
48-15 requirements, if the registration is required to dispense
49-16 the drug.
50-17 "Manufacturer" has the same meaning as defined in Section
51-18 15 of the Wholesale Drug Distribution Licensing Act.
52-19 "Pharmacist" means an individual licensed to engage in the
53-20 practice of pharmacy under the Pharmacy Practice Act or
54-21 licensed to engage in the practice of pharmacy in another
55-22 state.
56-23 "Practitioner" means a person licensed in this State to
57-24 dispense or administer drugs or who is licensed in another
58-25 state as a person authorized to dispense or administer drugs.
59-26 "Prescription drug" means any prescribed drug that may be
40+104TH GENERAL ASSEMBLY State of Illinois 2025 and 2026 HB2346 Introduced , by Rep. Laura Faver Dias SYNOPSIS AS INTRODUCED:
41+410 ILCS 715/5410 ILCS 715/45410 ILCS 715/55410 ILCS 715/70 new 410 ILCS 715/5 410 ILCS 715/45 410 ILCS 715/55 410 ILCS 715/70 new
42+410 ILCS 715/5
43+410 ILCS 715/45
44+410 ILCS 715/55
45+410 ILCS 715/70 new
46+Amends the Illinois Drug Reuse Opportunity Program Act. Requires the Illinois Department of Public Health: (1) to develop, maintain, and publish on its website information regarding the names and locations of pharmacies participating in the program; (2) to educate pharmacies in the State about the program and how to participate in it voluntarily; (3) to develop and publish educational materials to allow program participants and the Department to inform the general public about the purposes and benefits of the program; and (4) to collect information from participants and publish the information in an annual report to the General Assembly by December 31 of each calendar year, beginning December 31, 2026. Specifies that records maintained under the Act are subject to access by the Department upon request. Defines "Department".
47+LRB104 06540 BDA 16576 b LRB104 06540 BDA 16576 b
48+ LRB104 06540 BDA 16576 b
49+A BILL FOR
6050
6151
6252
6353
6454
65- HB2346 Engrossed - 2 - LRB104 06540 BDA 16576 b
55+410 ILCS 715/5
56+410 ILCS 715/45
57+410 ILCS 715/55
58+410 ILCS 715/70 new
6659
6760
68-HB2346 Engrossed- 3 -LRB104 06540 BDA 16576 b HB2346 Engrossed - 3 - LRB104 06540 BDA 16576 b
69- HB2346 Engrossed - 3 - LRB104 06540 BDA 16576 b
70-1 legally dispensed by a pharmacy. "Prescription drug" does not
71-2 include a drug for the treatment of cancer that can only be
72-3 dispensed to a patient registered with the drug manufacturer
73-4 in accordance with the federal Food and Drug Administration's
74-5 requirements.
75-6 "Priority patient" means an eligible patient who is an
76-7 Illinois resident and who is indigent, uninsured,
77-8 underinsured, or enrolled in a public health benefits program.
78-9 "Recipient" means any person or entity legally authorized
79-10 to possess medicine with a license or permit in the state in
80-11 which the person or entity is located, including, but not
81-12 limited to, a wholesaler or distributor, reverse distributor,
82-13 repackager, hospital, pharmacy, or clinic.
83-14 "Returns processor" has the same meaning as defined in
84-15 paragraph (18) of 21 U.S.C. 360eee. "Returns processor"
85-16 includes, but is not limited to, a reverse distributor.
86-17 "Unopened tamper-evident packaging" has the same meaning
87-18 as defined in the United States Pharmacopeia (USP) General
88-19 Chapter 659, Packaging and Storage Requirements, including,
89-20 but not limited to, unopened unit-dose, multiple-dose,
90-21 immediate, secondary, and tertiary packaging.
91-22 (Source: P.A. 102-389, eff. 1-1-22.)
92-23 (410 ILCS 715/45)
93-24 Sec. 45. Recordkeeping requirements. When performing any
94-25 action associated with a program under this Act or otherwise
61+
62+ LRB104 06540 BDA 16576 b
9563
9664
9765
9866
9967
100- HB2346 Engrossed - 3 - LRB104 06540 BDA 16576 b
10168
10269
103-HB2346 Engrossed- 4 -LRB104 06540 BDA 16576 b HB2346 Engrossed - 4 - LRB104 06540 BDA 16576 b
104- HB2346 Engrossed - 4 - LRB104 06540 BDA 16576 b
105-1 processing a donated drug for tax, manufacturer, or other
106-2 credit, a recipient shall be considered to be acting as a
107-3 returns processor and shall comply with all recordkeeping
108-4 requirements for nonsalable nonsaleable returns under federal
109-5 law. Records maintained under this Act may be accessed by the
110-6 Department upon request.
111-7 (Source: P.A. 102-389, eff. 1-1-22.)
112-8 (410 ILCS 715/55)
113-9 Sec. 55. Retention of records. All records required under
114-10 this Act shall be retained in physical or electronic format
115-11 and on or off the recipient's premises for a period of 6 years.
116-12 Donors or recipients may contract with one another or a third
117-13 party to create or maintain records on each other's behalf. An
118-14 identifier, such as a serial number or bar code, may be used in
119-15 place of any or all information required by a record or label
120-16 pursuant to this Act if it allows for such information to be
121-17 readily retrievable. Upon request by a State or federal
122-18 regulatory agency, the identifier used for requested records
123-19 shall be replaced with the original information. An identifier
124-20 shall not be used on patient labels when dispensing or
125-21 administering a drug. Records maintained under this Act may be
126-22 accessed by the Department upon request.
127-23 (Source: P.A. 102-389, eff. 1-1-22.)
128-24 (410 ILCS 715/70 new)
70+
71+
72+ HB2346 LRB104 06540 BDA 16576 b
73+
74+
75+HB2346- 2 -LRB104 06540 BDA 16576 b HB2346 - 2 - LRB104 06540 BDA 16576 b
76+ HB2346 - 2 - LRB104 06540 BDA 16576 b
77+1 drug manufacturers, repackagers, relabelers, outsourcing
78+2 facilities, health care facilities operated by the U.S.
79+3 Department of Veterans Affairs, and prisons.
80+4 "Drug" means a prescription drug, over-the-counter drug,
81+5 or supplies needed to administer a prescription or
82+6 over-the-counter drug.
83+7 "Eligible patient" means an individual:
84+8 (1) with a prescription for the drug, if a
85+9 prescription is required to dispense the drug, or who
86+10 reports symptoms treated by the drug if the drug is
87+11 over-the-counter; and
88+12 (2) who is registered with the drug's manufacturer in
89+13 accordance with federal Food and Drug Administration
90+14 requirements, if the registration is required to dispense
91+15 the drug.
92+16 "Manufacturer" has the same meaning as defined in Section
93+17 15 of the Wholesale Drug Distribution Licensing Act.
94+18 "Pharmacist" means an individual licensed to engage in the
95+19 practice of pharmacy under the Pharmacy Practice Act or
96+20 licensed to engage in the practice of pharmacy in another
97+21 state.
98+22 "Practitioner" means a person licensed in this State to
99+23 dispense or administer drugs or who is licensed in another
100+24 state as a person authorized to dispense or administer drugs.
101+25 "Prescription drug" means any prescribed drug that may be
102+26 legally dispensed by a pharmacy. "Prescription drug" does not
129103
130104
131105
132106
133107
134- HB2346 Engrossed - 4 - LRB104 06540 BDA 16576 b
108+ HB2346 - 2 - LRB104 06540 BDA 16576 b
135109
136110
137-HB2346 Engrossed- 5 -LRB104 06540 BDA 16576 b HB2346 Engrossed - 5 - LRB104 06540 BDA 16576 b
138- HB2346 Engrossed - 5 - LRB104 06540 BDA 16576 b
139-1 Sec. 70. Program support provided by the Department.
140-2 (a) The Department shall:
141-3 (1) develop, maintain, and publish on its website
142-4 information regarding the names and locations of
143-5 pharmacies participating in the Illinois Drug Reuse
144-6 Opportunity Program;
145-7 (2) educate pharmacies in the State about the Illinois
146-8 Drug Reuse Opportunity Program and how to participate in
147-9 it voluntarily;
148-10 (3) develop and publish educational materials to allow
149-11 program participants and the Department to inform the
150-12 general public about the purposes and benefits of the
151-13 program; and
152-14 (4) collect information from participants and publish
153-15 the information in an annual report to the General
154-16 Assembly by December 31 of each calendar year, beginning
155-17 December 31, 2026.
156-18 (b) Pharmacy participants are required to notify the
157-19 Department of their participation in any program under this
158-20 Act and report any data required in a format established by the
159-21 Department.
111+HB2346- 3 -LRB104 06540 BDA 16576 b HB2346 - 3 - LRB104 06540 BDA 16576 b
112+ HB2346 - 3 - LRB104 06540 BDA 16576 b
113+1 include a drug for the treatment of cancer that can only be
114+2 dispensed to a patient registered with the drug manufacturer
115+3 in accordance with the federal Food and Drug Administration's
116+4 requirements.
117+5 "Priority patient" means an eligible patient who is an
118+6 Illinois resident and who is indigent, uninsured,
119+7 underinsured, or enrolled in a public health benefits program.
120+8 "Recipient" means any person or entity legally authorized
121+9 to possess medicine with a license or permit in the state in
122+10 which the person or entity is located, including, but not
123+11 limited to, a wholesaler or distributor, reverse distributor,
124+12 repackager, hospital, pharmacy, or clinic.
125+13 "Returns processor" has the same meaning as defined in
126+14 paragraph (18) of 21 U.S.C. 360eee. "Returns processor"
127+15 includes, but is not limited to, a reverse distributor.
128+16 "Unopened tamper-evident packaging" has the same meaning
129+17 as defined in the United States Pharmacopeia (USP) General
130+18 Chapter 659, Packaging and Storage Requirements, including,
131+19 but not limited to, unopened unit-dose, multiple-dose,
132+20 immediate, secondary, and tertiary packaging.
133+21 (Source: P.A. 102-389, eff. 1-1-22.)
134+22 (410 ILCS 715/45)
135+23 Sec. 45. Recordkeeping requirements. When performing any
136+24 action associated with a program under this Act or otherwise
137+25 processing a donated drug for tax, manufacturer, or other
160138
161139
162140
163141
164142
165- HB2346 Engrossed - 5 - LRB104 06540 BDA 16576 b
143+ HB2346 - 3 - LRB104 06540 BDA 16576 b
144+
145+
146+HB2346- 4 -LRB104 06540 BDA 16576 b HB2346 - 4 - LRB104 06540 BDA 16576 b
147+ HB2346 - 4 - LRB104 06540 BDA 16576 b
148+1 credit, a recipient shall be considered to be acting as a
149+2 returns processor and shall comply with all recordkeeping
150+3 requirements for nonsalable nonsaleable returns under federal
151+4 law. Records maintained under this Act may be accessed by the
152+5 Department upon request.
153+6 (Source: P.A. 102-389, eff. 1-1-22.)
154+7 (410 ILCS 715/55)
155+8 Sec. 55. Retention of records. All records required under
156+9 this Act shall be retained in physical or electronic format
157+10 and on or off the recipient's premises for a period of 6 years.
158+11 Donors or recipients may contract with one another or a third
159+12 party to create or maintain records on each other's behalf. An
160+13 identifier, such as a serial number or bar code, may be used in
161+14 place of any or all information required by a record or label
162+15 pursuant to this Act if it allows for such information to be
163+16 readily retrievable. Upon request by a State or federal
164+17 regulatory agency, the identifier used for requested records
165+18 shall be replaced with the original information. An identifier
166+19 shall not be used on patient labels when dispensing or
167+20 administering a drug. Records maintained under this Act may be
168+21 accessed by the Department upon request.
169+22 (Source: P.A. 102-389, eff. 1-1-22.)
170+23 (410 ILCS 715/70 new)
171+24 Sec. 70. Program support provided by the Department. The
172+
173+
174+
175+
176+
177+ HB2346 - 4 - LRB104 06540 BDA 16576 b
178+
179+
180+HB2346- 5 -LRB104 06540 BDA 16576 b HB2346 - 5 - LRB104 06540 BDA 16576 b
181+ HB2346 - 5 - LRB104 06540 BDA 16576 b
182+
183+
184+
185+
186+
187+ HB2346 - 5 - LRB104 06540 BDA 16576 b